# SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer

Source: https://onco.cc/trials/nct06373133/  
OnCo record `nct06373133` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SHR-8068 and adebrelimab in colorectal cancer, run by West China Hospital, not yet recruiting.

## Summary

SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer is a phase 1/2, interventional study registered as NCT06373133 by West China Hospital, with a registry enrolment figure of 36 participants, started 2024-05-01 and due to reach its primary completion in 2026-11-01. Interventions recorded: SHR-8068; Adebrelimab; BP102. Conditions listed: Colorectal Cancer. Primary outcome: Dose-limiting toxicity; PFS. Colorectal eligibility wording from the registry: "pathologically confirmed metastatic colorectal adenocarcinoma;". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06373133
- Phase: 1/2
- Setting: An Exploratory Clinical Trial of SHR-8068 Combined With Aldebelizumab and BP102 in the Treatment of Refractory Colorectal Cancer
- Sponsor: West China Hospital
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT06373133: https://clinicaltrials.gov/study/NCT06373133

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [SHR-8068](https://onco.cc/drugs/shr-8068/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06373133.json